Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.33 |
| ▸ | HTR1A | P08908 | 2/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1428067 | 0.85 | EPHX1 (0.34) | KDM1ACACNA1HCARM1PRMT6HTR1A | |
| SCHEMBL1430764 | 0.78 | GNAI3 (0.41) | CARM1PRMT6ALOX15POLBHTT | |
| SCHEMBL1428056 | 0.72 | CTSS (0.34) | — | |
| SCHEMBL1428801 | 0.72 | KDM1A (0.46) | KDM1ACACNA1HALDH1A1 | |
| SCHEMBL5312840 | 0.72 | TACR2 (0.38) | — | |
| SCHEMBL1428097 | 0.71 | KDM1A (0.41) | KDM1ACACNA1HCARM1PRMT6HTR1A | |
| SCHEMBL2276120 | 0.71 | TP53 (0.34) | ALDH1A1POLBHTT | |
| SCHEMBL1428804 | 0.71 | KDM1A (0.45) | KDM1A | |
| SCHEMBL27872387 | 0.69 | KDM1A (0.47) | KDM1ACARM1PRMT6ALDH1A1DRD2 | |
| SCHEMBL7797385 | 0.68 | DRD2 (0.43) | KDM1ACACNA1HDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065926-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MARK G. DEGIACOMO, CHAPTER 7 TRUSTEE OF EPIRUS BIOPHARMACEUTICALS, INC. | 2013-03-14 | — | — | US | disclosed |
| EP-2300007-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Zalicus Pharmaceuticals Ltd. (CA) | 2011-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065926-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | KDM1A 3578/4885CACNA1H 2/4885CARM1 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.